Multi Vessel Coronary Artery Disease

Cardiovascular
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Xeltis
XeltisNetherlands - Eindhoven
1 program
CABGN/A1 trial
Active Trials
NCT04545112Enrolling By InvitationEst. Feb 2031
CathWorks
CathWorksCA - Newport Beach
1 program
FFRangioN/A1 trial
Active Trials
NCT03455244CompletedEst. May 2018
Abbott
AbbottABBOTT PARK, IL
1 program
PressureWire Certus guidewireN/A1 trial
Active Trials
NCT02325973Completed242Est. Feb 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
XeltisCABG
CathWorksFFRangio
AbbottPressureWire Certus guidewire

Clinical Trials (3)

Total enrollment: 242 patients across 3 trials

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)

Start: Oct 2020Est. completion: Feb 2031
N/AEnrolling By Invitation

Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease

Start: Nov 2017Est. completion: May 2018
N/ACompleted
NCT02325973AbbottPressureWire Certus guidewire

Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI

Start: Jun 2013Est. completion: Feb 2018242 patients
N/ACompleted

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space